<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04385082</url>
  </required_header>
  <id_info>
    <org_study_id>19-000876</org_study_id>
    <secondary_id>R01DA047296</secondary_id>
    <nct_id>NCT04385082</nct_id>
  </id_info>
  <brief_title>Cannabis Effects as a Function of Sex (CanSex)</brief_title>
  <acronym>CanSex</acronym>
  <official_title>Sex-dependent Effects of Cannabis: Assessing Analgesic, Abuse-related and Pharmacokinetic Differences Between Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to assess the impact of cannabis on the analgesic and&#xD;
      abuse-related effects between men and women&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will compare smoked cannabis's dose-dependent, analgesic and abuse-related&#xD;
      effects between men and women and variables that underlie these sex-dependent differences,&#xD;
      including pharmacokinetics of THC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a randomized, double-blind, placebo-controlled study. All participants will complete all dose conditions in a randomized order.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject-rated drug effects</measure>
    <time_frame>5 hours</time_frame>
    <description>Average and peak subjective ratings of drug effects associated with abuse liability as measured using visual analogue scales (VAS; 1-100mm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analgesia as measured using the Cold Pressor Test</measure>
    <time_frame>5 hours</time_frame>
    <description>Peak and average pain threshold and tolerance assessed using the Cold Pressor Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of THC and metabolites</measure>
    <time_frame>5 hours</time_frame>
    <description>Plasma levels of THC, 11-OH-THC, and THCCOOH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug reinforcement using the cannabis self-administration task</measure>
    <time_frame>5 hours</time_frame>
    <description>Average number of cannabis puffs self-administered as a function of cannabis strength and sex. For this task, up to three 'puffs' of cannabis may be chosen for self-administration during each session.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Pain</condition>
  <condition>Abuse, Drug</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Smoked Cannabis (~0% THC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low strength cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked Cannabis (~4% THC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher strength cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Smoked Cannabis (~10% THC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Cannabis</intervention_name>
    <description>Smoked cannabis with THC</description>
    <arm_group_label>Higher strength cannabis</arm_group_label>
    <arm_group_label>Low strength cannabis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Cannabis</intervention_name>
    <description>Placebo smoked cannabis (no THC)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant female aged 21-55 years&#xD;
&#xD;
          -  Report use of cannabis an average of 1-7 days per week&#xD;
&#xD;
          -  Not currently seeking treatment for their cannabis use&#xD;
&#xD;
          -  Urine test positive for recent cannabis use for heavy users&#xD;
&#xD;
          -  No reported adverse effects with cannabis smoking in light users&#xD;
&#xD;
          -  Have a Body Mass Index from 18.5 - 34kg/m2.&#xD;
&#xD;
          -  Able to perform all study procedures&#xD;
&#xD;
          -  FEMALES: Currently practicing a non-hormonal effective form of birth control&#xD;
&#xD;
          -  FEMALES: Must be regularly cycling&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meeting DSM-V criteria for any substance use disorder other than nicotine, caffeine,&#xD;
             or cannabis use disorder&#xD;
&#xD;
          -  Report using other illicit drugs in the prior 4 weeks&#xD;
&#xD;
          -  History or current evidence of severe psychiatric illness or medical condition judged&#xD;
             by the study physician and PI to put the participant at greater risk of experiencing&#xD;
             adverse events due to completion of study procedures, interfere with their ability to&#xD;
             participate in the study, or their capacity to provide informed consent.&#xD;
&#xD;
          -  Current use of medical cannabis, prescription analgesics, or any medications that may&#xD;
             affect study outcomes&#xD;
&#xD;
          -  Current pain&#xD;
&#xD;
          -  Insensitivity to the cold water stimulus of the Cold Pressor Test&#xD;
&#xD;
          -  FEMALES: using a hormonal contraceptive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziva Cooper, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ziva Cooper, PhD</last_name>
    <phone>310-206-9942</phone>
    <email>zcooper@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vincent Acebo</last_name>
    <phone>310-983-3417</phone>
    <email>vacebo@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziva Cooper, Phd</last_name>
      <phone>310-206-9942</phone>
      <email>zcooper@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vincent Acebo</last_name>
      <phone>310-983-3417</phone>
      <email>vacebo@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ziva Cooper, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Ziva D. Cooper, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Cannabis</keyword>
  <keyword>THC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

